Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 56(3); 2024 > Article
Original Article
Gastrointestinal cancer The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study
Young Hoon Chang1orcid, Cheol Min Shin1,orcid, Kyungdo Han2,orcid, Jin Hyung Jung3, Eun Hyo Jin4, Joo Hyun Lim4, Seung Joo Kang4, Yoon Jin Choi1,5, Hyuk Yoon1, Young Soo Park1, Nayoung Kim1, Dong Ho Lee1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2024;56(3):825-837.
DOI: https://doi.org/10.4143/crt.2023.753
Published online: December 20, 2023

1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

2Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea

3Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Korea

4Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea

5Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Correspondence: Cheol Min Shin, Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam 13620, Korea
Tel: 82-31-787-7057 Fax: 82-31-787-4052 E-mail: scm6md@gmail.com
Co-correspondence: Kyungdo Han, Department of Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul 06978, Korea
Tel: 82-2-820-7025 Fax: 82-2-823-1746 E-mail: hkd917@naver.com
• Received: June 12, 2023   • Accepted: December 19, 2023

Copyright © 2024 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 3,167 Views
  • 112 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    The incidence of early-onset colorectal cancer (EoCRC) is increasing worldwide. The association between hypertriglyceridemia (HTG) and EoCRC risk remains unclear.
  • Materials and Methods
    We conducted a nationwide cohort study of 3,340,635 individuals aged 20-49 years who underwent health checkups between 2009 and 2011 under the Korean National Health Insurance Service. HTG was defined as serum triglyceride (TG) level ≥ 150 mg/dL. According to the change in TG status, participants were categorized into persistent normotriglyceridemia (NTG; group 1), NTG to HTG (group 2), HTG to NTG (group 3), and persistent HTG (group 4) groups. The EoCRC incidence was followed up until 2019.
  • Results
    In total, 7,492 EoCRC cases developed after a mean of 6.05 years of follow-up. Group 4 had the highest risk of EoCRC (adjusted hazard ratio [aHR], 1.097; 95% confidence interval [CI], 1.025 to 1.174). While the risk of rectal cancer was significantly increased in groups 3 and 4 (aHR [95% CI], 1.236 [1.076 to 1.419] and 1.175 [1.042-1.325], respectively), no significant risk differences were observed in right colon cancer. In group 4, male sex and diabetes were associated with a further increased risk of EoCRC (aHR [95% CI], 1.149 [1.082 to 1.221] and 1.409 [1.169 to 1.699], respectively). In addition, there was a dose-response relationship between serum TG levels and the risk of EoCRC (p for trends < 0.0001).
  • Conclusion
    Persistent HTG increased the risk of EoCRC, which was significantly higher only for rectal cancer and marginally higher for other colonic subsites.
  • Key words: Colorectal neoplasms, Young-adult, Hypertriglyceridemia
Although the global incidence of early-onset colorectal cancer (EoCRC) is increasing [1], its associated risk factors need further verification [2]. Both late-onset CRC (LoCRC) and EoCRC share similar risk factors, such as metabolic syndrome and prolonged sedentary behavior [1]. However, there is a lack of research on whether these conventional risk factors actually have a greater effect on EoCRC than on LoCRC. With the worldwide increase in obesity and dyslipidemia rates, especially in younger generations, revealing the connections between these risk factors and coincident EoCRC is essential to reducing the incidence of EoCRC.
Triglyceride (TG), a sensitive surrogate marker of obesity, is an important link between obesity and EoCRC. Hypertriglyceridemia (HTG), the hallmark of dyslipidemia in obesity, leads to metabolic syndrome by inducing insulin resistance [3]. Although high TG levels are associated with increased cardiovascular risk [4], and active prospective trials to lower TG levels have been conducted, the importance of HTG in EoCRC has not been considered in depth. Previous studies on TG and CRC mostly focused on CRC at all ages [5], and their results were inconsistent due to cross-sectional or casecontrol designs, short follow-up durations, limited sample size, and lack of confounding factor adjustments [5-7].
South Korea has confronted EoCRC at a rapid pace in recent decades. According to cancer registration data covering the period between 2008 and 2012 for 42 countries, South Korea had the highest occurrence of colorectal cancer at an earlier age [8]. We conducted a large nationwide population-based cohort study in South Korea to identify a direct association between TG levels and EoCRC. The secondary aim was to evaluate whether the HTG-associated risk of EoCRC differs according to tumor subsites and serum TG levels.
1. Study design
This was a retrospective study of data collected from the National Healthcare Insurance Service (NHIS) of South Korean young adults (20-49 years old) who underwent health check-ups between 2009 and 2011. Based on serum TG status, we tracked these participants until 2019 to observe whether they newly developed CRCs before age 50.
2. Data source
The Ministry of Health and Welfare of the Republic of Korea manages the NHIS. The NHIS has provided free health examinations at least biennially to all the employee-insured subscribers aged ≥ 20 years. The checkup program data included demographic information, socioeconomic status, anthropometric measurements, health-related questionnaires, and laboratory tests.
3. Study population
The entire enrollment process for the study cohort is shown in Fig. 1. We initially included 10,628,070 Korean citizens who had undergone health checkups in 2009. In total, 6,902,420 individuals underwent health checkups between 2009 and 2011. When we excluded participants aged > 50 years in 2011 (the index year for enrollment), the remaining population was 3,600,560. We excluded 221,944 participants with incomplete health check-up data. In total, 35,223 participants who were previously diagnosed with malignancy before 2011 were excluded. To avoid including people with pre-existing CRC, 2,758 individuals who developed CRC after 1 year of enrollment in 2011 were excluded. Finally, 3,340,635 participants were included in the analysis and followed up until 2019. Fig. 2 shows the follow-up process for each participant according to TG status. When the participants reached age 50, they were censored from the main analysis.
4. Data collection
Anthropometric measurements included height, weight, waist circumference (WC), and blood pressure. Laboratory tests included serum fasting glucose (FBS), total cholesterol (TC), TG, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Blood tests were performed after an overnight fasting for at least 8 hours. Standardized self-reported questionnaires were used to evaluate health behaviors, including demographic information (age, sex, and income status), smoking status, alcohol consumption, and regular exercise. The NHIS claims data were used to identify comorbidities (hypertension [HTN], diabetes mellitus [DM], and anti-dyslipidemia medications).
5. Definitions of HTG and other covariates
We defined HTG as fasting serum TG level ≥ 150 mg/dL, according to a scientific statement from the American Heart Association [9]. The 1st exam was conducted in 2009. The 2nd exam was conducted in 2011. Our index date was 2011, and all baseline characteristics and covariates were based on the index year. We divided the enrolled participants into four groups based on TG status in 2009 and 2011: the “persistent normotriglyceridemia (NTG)” group (serum TG < 150 mg/dL at both the 1st and the 2nd exams, group (1), “NTG to HTG” group (serum TG < 150 mg/dL at the 1st exam and TG ≥ 150 mg/dL at the 2nd exam, group (2) and “HTG to NTG” group (serum TG ≥ 150 mg/dL at the 1st exam and TG < 150 mg/dL at the 2nd exam, group (3) “persistent HTG” group (serum TG ≥ 150 mg/dL at both the 1st and 2nd exams, group (4) [10]. We hypothesized that group 3 would result in a decreased risk of EoCRC compared to group 4, while group 4 would result in an increased risk compared to group 1. Based on TG levels derived from 2011, we stratified TG levels into quartiles (Q1: < 71 mg/dL, Q2: 71-104 mg/dL, Q3: 105-160 mg/dL, Q4: ≥ 161 mg/dL). To minimize confounding by sex, subgroup analyses were performed by applying sex-specific TG quartile cut-off values (male Q1: < 71 mg/dL, Q2: 71-104 mg/dL, Q3: 105-160 mg/dL, Q4: ≥ 161 mg/dL; female Q1: < 56 mg/dL, Q2: 57-76 mg/dL, Q3: 77-107 mg/dL, Q4: ≥ 108 mg/dL). Individuals were classified as current smokers if they responded as smokers in the survey conducted in 2011. We categorized alcohol consumption as either none or heavy drinkers who consumed > 30 g of alcohol per day. Regular exercise was defined as moderate-intensity physical activity for more than 5 days per week or vigorous exercise for more than 3 days per week. Income levels were classified into four groups according to income quartiles. The first quartile (Q1) was a group that received medical aid and was included in the bottom 25% of income. Since the definition of obesity varies by ethnicity and our study focuses on South Koreans, we followed the American Association of Clinical Endocrinologists/American College of Endocrinology comprehensive clinical practice guidelines and defined a body mass index (BMI) ≥ 25 kg/m2 as obese [11]. The presence of abdominal obesity was defined as a WC ≥ 90 cm for males and ≥ 85 cm for females [12]. Comorbidities were defined using ICD-10-CM (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision Clinical Modification) codes because all diagnoses and prescription codes are gathered according to ICD-10-CM codes by the NHIS. DM was defined based on codes E11-14 with antidiabetic medications or FBS levels above 126 mg/dL. HTN was defined based on ICD-10-CM codes I10-13 and I15 with antihypertensive medications or blood pressure ≥ 140/90 mmHg. Anti-dyslipidemia medications were defined as claims for prescriptions of dyslipidemia medications, including statin, ezetimibe, and fibrate.
6. Study outcomes
The primary outcome was the incidence of newly diagnosed EoCRC after the second health examination in 2011, during the follow-up period until 2019. EoCRC was defined according to the ICD-10-CM codes. Each specific code is as follows: C18.0-18.4 for proximal colon cancer; C18.5-18.7, C19.0 for distal colon cancer; and C20.0 for rectal cancer. The secondary outcome was the incidence of EoCRC according to tumor subsites.
7. Statistical analysis
Continuous variables are presented as mean±standard deviation, and categorical variables as numbers and percentages. An independent t-test or analysis of variance (ANOVA) was used to compare continuous variables. The chi-square test was used to analyze categorical variables. The incidence of EoCRC was calculated as the number of events per 1000 person-years. We used multivariable Cox proportional hazards regression models to calculate the hazard ratios and the corresponding 95% confidence intervals (CIs). Adjustments for covariates were performed for sex, age, smoking status, alcohol consumption, regular exercise, low income, obesity, WC, DM, HTN, and anti-dyslipidemia medications. Model 1 was unadjusted; Model 2 was adjusted for sex and age; Model 3 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, and low-income status; Model 4 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity (BMI ≥ 25 kg/m2), DM, HTN, and anti-dyslipidemia medications. Model 4* was adjusted for age, smoking status, alcohol consumption, regular exercise, low-income status, WC, DM, and HTN. To present the cumulative events of EoCRC according to TG status, Kaplan-Meier curves were used and compared using the log-rank test. We performed subgroup analysis using covariates to evaluate the effect of TG status change on the incidence of EoCRC. An interaction p analysis for each covariate subgroup was performed. Furthermore, to evaluate the effect of stratified TG levels on the incidence of EoCRC, we performed subgroup analysis with stratified TG levels. Two-sided p-values < 0.05 were considered statistically significant. All statistical analyses were performed using SAS ver. 9.3 (SAS Institute Inc., Cary, NC) and R ver. 3.2.3 (The R Foundation for Statistical Computing, Vienna, Austria).
1. Baseline characteristics of the study population
The baseline characteristics of the enrolled participants are shown in Table 1, S1 and S2 Tables. Of the 3,340,635 eligible study participants, 2,053,340, 380,412, 331,637, and 575,246 individuals were classified as groups 1, 2, 3, and 4, respectively. Group 1 participants had healthier indices: the lowest percentage of smokers (23.83%), drinkers (5.78%), obesity (20.50%), DM (1.98%), HTN (8.40%), and anti-dyslipidemia medications (1.50%). However, regarding socioeconomic status, group 1 had the highest percentage of participants in the lowest income quartile (14.53%). The prevalence of LDLC above 130 mg/dL and 160 mg/dL was highest in group 3 (36.62% and 11.12%, respectively). In group 4, the proportion of males was high (91.33%). Poorer health indices were mainly observed in group 4; the proportion of smokers (52.04%), drinkers (15.54%), and obese participants (58.34%) was higher in group 4 than in the other three groups; the highest proportion of the participants taking medication for DM (9.14%), HTN (23.32%), and dyslipidemia (7.16%) was observed in group 4; individuals in group 4 had the highest levels of body weight, BMI, WC, serum FBS and TC; and the proportion of low HDL-C was the lowest in group 4.
2. EoCRC risk according to the change in TG status by anatomic sites
Of the 3,340,635 participants, 7,492 EoCRC cases were reported during a mean follow-up of 6.05 years (Fig. 2, S1 Table). Kaplan-Meier curve showed that EoCRC risk was the highest in group 4 (Fig. 3). When the Kaplan-Meier analyses were conducted with stratification based on the tumor location, groups 3 and 4 had the higher risk for rectum and proximal colon cancers while group 1 showed an increased risk for overall colon and unspecified colon cancers (S3-S7 Figs.). In Cox regression analysis (Table 2), group 4 had the highest risk of the overall EoCRC development (model 4: aHR [95% CI], 1.097 [1.025 to 1.174]); the risk of rectal cancer was increased in both groups 3 and 4 (model 4: 1.236 [1.076 to 1.419] and 1.175 [1.042 to 1.325], respectively). However, there were no significant results in proximal, distal, and unspecified colon cancers in the models adjusted for confounding variables. Even after excluding patients taking lipid-lowering agents in 2009 or 2011, group 4 had the highest risk of EoCRC development (aHR [95% CI], 1.094 [1.019 to 1.174]); the risk of rectal cancer increased in both groups 3 and 4 after adjusting for confounding variables (1.203 [1.042 to 1.389] and 1.172 [1.036 to 1.327], respectively) (S8 Table). Thus, no significant difference in the risk of EoCRC development was noted regardless of the exclusion of the participants taking anti-dyslipidemic medications. Also, after additionally adjusting for WC instead of obesity (BMI ≥ 25 kg/m2) in model 4 (model 4*), the results were not substantially different (S9 Table). In contrast, there were no significant results according to the change in TG status in proximal, distal, and unspecified colon cancers (Table 2).
3. EoCRC risk according to TG quartiles by anatomic sites
Table 3 shows the association between serum TG levels derived from 2011 and the risk of developing EoCRC at different anatomical sites. Higher serum TG levels are associated with a higher risk of developing EoCRC. Under four-level stratification with TG status (Q1: < 71 mg/dL, Q2: 71-104 mg/dL, Q3: 105-160 mg/dL, Q4: ≥ 161 mg/dL), individuals in the higher TG quartile showed an increased risk for EoCRC compared with those in the lower TG quartile groups. After adjusting for confounding variables, individuals with the highest TG status (belonging to the Q4 group) had a 14.5% increased risk of EoCRC (1.145 [1.064 to 1.233]) compared with the reference Q1 group (p for trend=0.0002). In terms of tumor site, participants in the highest TG quartile (Q4) showed the highest risk of EoCRC for colon and distal colon cancers (1.144 [1.048 to 1.248] and 1.224 [1.020 to 1.469], respectively). When applying different criteria for TG quartiles depending on sex or performing analyses stratified by sex, individuals in the groups of the higher TG quartiles showed an increased risk for EoCRC (S10-S12 Tables).
4. EoCRC risk according to the change in TG status by subgroups
Table 4 presents subgroup analysis according to sex, age, smoking status, alcohol consumption, regular exercise, low income, obesity, DM, HTN, and anti-dyslipidemia medications. The participants were censored from the analysis if the incidence of CRC was above age 50. The adjusted hazard ratios and p for interaction were calculated for each subgroup to evaluate the effect of persistent HTG on the risk of EoCRC. The risks of EoCRC were higher in group 4 participants who were male, 30-39 years old, non-smokers, non-drinkers, non-regular exercisers, had low-income status, non-obese, without abdominal obesity, with DM, with HTN, and without anti-dyslipidemia medications. With the age-censored data, the association between the change in TG status and EoCRC risk was not significant according to the above-mentioned clinical factors (Table 4, all subgroups, pinteraction > 0.05).
By analyzing the subgroups with non-age-censored data, we found that the association between the change in TG status and the risk of EoCRC differed between males and females with DM (pinteraction=0.025 and 0.013, respectively) (S13 Table). Male individuals and those with DM from group 4 had higher risks of EoCRC (1.149 [1.082 to 1.221] and 1.409 [1.169 to 1.699], respectively). The anti-dyslipidemia subgroup showed a marginally significant p interaction (pinteraction=0.060) (S13 Table) while taking anti-dyslipidemia medications increased the risk of EoCRC in both groups 3 and 4 (1.434 [1.105 to 1.861] and 1.341 [1.073 to 1.677], respectively). Although LDL-C levels above 130 mg/dL and ≤ 160 mg/dL increased the risks of EoCRC (1.104 [1.007 to 1.210] and 1.122 [1.060 to 1.187], respectively), the association between changes in TG status and EoCRC risk did not differ significantly according to TC, LDL-C, and HDL-C levels.
Our findings suggest the possibility of using persistent HTG as a serial biochemical marker for predicting the risk of EoCRC. A recent meta-analysis of the previous 13 studies conducted from 1997 to 2019 revealed that HTG is associated with a high incidence and risk of CRC [5,6,13-25]. However, most studies included in the meta-analysis evaluated the association between HTG and colorectal cancer risk as a secondary outcome, and studies on the effect of HTG on EoCRC risk were rate (S14 Table). One study by Jung et al. [26] identified elevated TG levels as a risk factor for both overall and advanced colorectal neoplasia in the younger population. Recently, Jin et al. [8] found an increased risk of EoCRC in patients with HTG. However, TG was not the primary interest of all these studies, and only a single-point evaluation of TG was performed before the diagnosis of EoCRC. Our study overcame these limitations, further adjusted for obesity indicators, and eventually found a 10% risk increase in EoCRC in individuals with HTG persistence long before the diagnosis of CRC. Therefore, our findings confirmed that HTG alone increases the risk of EoCRC, as suggested by previous observational studies.
In line with the high incidence of EoCRC in the rectum, our study found that persistent HTG develops EoCRC more frequently in overall colorectal sites, especially the rectum [7]. Previous studies on EoCRC have found strong associations between the primary risk factors of EoCRC and rectal cancers. Therefore, the interaction between TG and rectal carcinogenesis should be evaluated further in future studies. Interestingly, group 3 and group 4 had a higher risk of EoCRC in the rectum. A plausible explanation for the higher EoCRC risk shown in group 3 might be that individuals from group 3 may have undergone lifestyle modifications or TG-lowering medications after learning their HTG status in 2009.
Increasing serum TG levels were associated with a higher risk of EoCRC. Borena et al. found a positive association between TG levels and CRC incidence in men [6]. Our observations underscore the need for biological investigation of the interaction between TG and EoCRC carcinogenesis in the distal colon and rectum in the context of molecular histopathologic profiles.
In our non-age-censored data, we found significant interactions between HTG persistence and EoCRC risk in males and individuals with diabetes. Although the male sex is a well-known risk factor for both overall CRC and EoCRC, the mechanism of carcinogenesis remains unclear. Since HTG is closely related to visceral obesity, variations in visceral fat distribution between males and females could explain the differing risks of EoCRC. However, this association persists even after adjusting for WC, a proxy for visceral obesity Therefore, HTG may be associated with EoCRC risk independently of its association with visceral obesity. Furthermore, the protective effect of estrogen and progesterone may be attributed to the lower risk of EoCRC in females [27]. Regarding diabetes, a prior meta-analysis demonstrated a 1.3-fold increase in CRC risk in patients with diabetes [28]. However, a direct relationship between DM and EoCRC has not been widely reported. Due to the age-specific nature of diabetic incidence, possibly a significant interaction was only observed in non-age-censored data. Further research is required to validate the mechanism by which TG interacts with DM to increase the risk of EoCRC.
The biological mechanism by which TG induces EoCRC remains unclear. Lipid metabolism, intestinal microbiota, and cellular stress responses may be involved in the development of EoCRC [1,29]. Most importantly, CRC requires lipids for proliferation. Ecker et al. [30] quantified the comprehensive lipidome of CRC tissues and showed that a high TG signature has prognostic value in patients with CRC. Several mechanisms may explain the association between dyslipidemia and CRC development. Since cancer cells require lipids for proliferation, higher ingestion of exogenous lipids may induce a constant supply of free fatty acids to CRC cells. Furthermore, chronic HTG can induce hyperinsulinemia and insulin resistance, which subsequently stimulate the production of reactive oxygen species and contribute to carcinogenesis by damaging cellular DNA [26]. Additionally, there are studies investigating the role of the intestinal microbiota in regulating lipid metabolism [27]; they speculate that some intestinal microorganisms such as Fusobacterium nucleatum, Bacteroides fragilis, and Bifidobacterium species might contribute to EoCRC tumorigenesis through interaction with excess TG. However, the causal relationship between HTG and EoCRC through intestinal microorganisms is elusive and needs further studies.
To the best of our knowledge, this is the first study to consider the implementation of HTG investigations in association with EoCRCs. The chronic effects of lipotoxicity induced by HTG have not been previously investigated in detail. Nevertheless, this study had several limitations. First, we gathered retrospective nationwide data only from South Koreans. However, since we evaluated the effect of HTG persistence in ethnicities experiencing a rapid increase in dyslipidemia, this study’s design can be applied to other ethnicities and be used to evaluate the causality between HTG and EoCRC. Second, we could not exclude all individuals who have an IBD. Third, we could not identify individuals with a family history of CRC, which is also an important risk factor for EoCRC. Fourth, secondary causes of HTG were not fully excluded from the claims data. Fifth, we could not identify hereditary colon cancers in our claims data. Sixth, analyzing EoCRC based on the genetic and epigenetic profiles of EoCRC tumors may be needed to further categorize sub-populations with a higher risk of developing EoCRC. Recent evidence shows that MSI-high accounts for 10%-30% of EoCRCs compared to 15% of all CRCs [1]. Seventh, since we did not know which stage of each EoCRC patient was diagnosed, sub-analysis according to the EoCRC stage was impossible. Eighth, information on host genetic factors or early-life exposures, such as diet during the prenatal period and childhood, was lacking. It would have been valuable to evaluate the differences in EoCRC incidences according to these factors since studies on the effect of early life exposures on EoCRC are still lacking [1]. Ninth, had gut microbial specimens from each participant been collected, further evaluation of the association between gut microbiota and HTG on the risk of EoCRC would have been possible. Tenth, our analysis only covered the participants who received the national health checkups in both 2009 and 2011. Considering that people who do not receive regular checkups may have unhealthy lifestyle patterns, those who were not enrolled in the study may have had a higher risk of developing EoCRC. Lastly, the evolution of triglycerides during the follow-up period has not been considered.
In conclusion, our study demonstrated that the persistence of HTG is associated with a higher risk of EoCRC. Individuals in the HTG-persisted group who were male and had DM showed a higher risk of developing EoCRC. As the incidence of EoCRC increases, it is essential to focus on detecting modifiable risk factors for EoCRC. Among the many lipid components, TG has the potential to be a suitable screening marker for EoCRC. Based on our nationwide cohort study, we suggest cautious CRC screening for a younger population with persistent HTG to detect the incidence of EoCRC early.
Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).
crt-2023-753_S1_Table.pdf
crt-2023-753_S2_Table.pdf
crt-2023-753_S3_Fig.pdf
crt-2023-753_S4_Fig.pdf
crt-2023-753_S5_Fig.pdf
crt-2023-753_S6_Fig.pdf
crt-2023-753_S7_Fig.pdf
crt-2023-753_S8_Table.pdf
crt-2023-753_S9_Table.pdf
crt-2023-753_S10_Table.pdf
crt-2023-753_S11_Table.pdf
crt-2023-753_S12_Table.pdf
crt-2023-753_S13_Table.pdf
crt-2023-753_S14_Table.pdf

Ethical Statement

The study protocol was approved by the Institutional Review Board of Seoul National University of Bundang Hospital (IRB number: X-2210-785-901) and followed the Declaration of Helsinki. Informed consent was waived because the data were anonymous and retrospective.

Author Contributions

Conceived and designed the analysis: Shin CM, Han K.

Collected the data: Han K, Jung JH.

Contributed data or analysis tools: Han K, Jung JH.

Performed the analysis: Han K, Jung JH.

Wrote the paper: Chang YH, Shin CM.

Critical revision of the manuscript for important intellectual content: Jin EH, Lim JH, Kang SJ, Choi YJ, Yoon H, Park YS, Kim N, Lee DH.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgements
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C1140).
Fig. 1.
Flowchart showing the enrollment process for the study cohort. CRC, colorectal cancer.
crt-2023-753f1.jpg
Fig. 2.
Flowchart showing the follow-up process of each participant according to triglyceride (TG) status in 2009 and 2011; group 1 (serum TG < 150 mg/dL both in 2009 and 2011), group 2 (serum TG < 150 mg/dL in 2009 and TG ≥ 150 mg/dL in 2011), group 3 (serum TG ≥ 150 mg/dL in 2009 and TG < 150 mg/dL in 2011), and group 4 (serum TG ≥ 150 mg/dL both in 2009 and 2011). EoCRC, early-onset colorectal cancer.
crt-2023-753f2.jpg
Fig. 3.
Kaplan-Meier curves depicting the incidence probability for colorectal cancer according to change in triglyceride (TG) status; normal TG-persisted (group 1), normal to hypertriglyceridemia (HTG) (group 2), HTG to normal (group 3) and HTG-persisted (group 4) groups, if incidence age > 50 then censored (p=0.001 by log-rank test).
crt-2023-753f3.jpg
Table 1.
Baseline characteristics of enrolled National Health Insurance Service cohort in 2011 according to TG change status from 2009-2011
Characteristic Total (n=3,340,635) TG change
 p-value
Group 1 (n=2,053,340) Group 2 (n=380,412) Group 3 (n=331,637) Group 4 (n=575,246)
Male sex 2,122,940 (63.55) 1,033,338 (50.32) 300,970 (79.12) 263,256 (79.38) 525,376 (91.33) < 0.001
Age at recruitment (yr) 38.32±6.90 37.73±7.20 38.53±6.60 39.34±6.36 39.72±5.91 < 0.001
 20-29 433,246 (12.97) 342,650 (16.69) 38,476 (10.11) 24,975 (7.53) 27,145 (4.72) < 0.001
 30-39 1,274,575 (38.15) 750,788 (36.56) 158,592 (41.69) 129,336 (39.00) 235,859 (41.00)
 40-49 1,632,814 (48.88) 959,902 (46.75) 183,344 (48.20) 177,326 (53.47) 312,242 (54.28)
Current smoker 1,079,951 (32.33) 489,245 (23.83) 158,728 (41.73) 132,645 (40.00) 299,333 (52.04) < 0.001
Heavy alcohol drinkera) 289,752 (8.67) 118,700 (5.78) 45,604 (11.99) 36,063 (10.87) 89,385 (15.54) < 0.001
Regular exerciseb) 583,556 (17.47) 361,457 (17.60) 60,225 (15.83) 68,297 (20.59) 93,577 (16.27) < 0.001
Low incomec) 424,479 (12.71) 298,342 (14.53) 41,102 (10.80) 36,254 (10.93) 48,781 (8.48) < 0.001
Obesityd) 1,053,807 (31.55) 420,895 (20.50) 167,891 (44.13) 129,419 (39.02) 335,602 (58.34) < 0.001
Diabetes mellitus 130,071 (3.89) 40,703 (1.98) 18,831 (4.95) 17,979 (5.42) 52,558 (9.14) < 0.001
Hypertension 423,587 (12.68) 172,561 (8.40) 62,449 (16.42) 54,413 (16.41) 134,164 (23.32) < 0.001
Anti-dyslipidemia medications 102,555 (3.07) 30,863 (1.50) 12,182 (3.20) 18,348 (5.53) 41,162 (7.16) < 0.001
Height (cm) 167.52±8.46 165.99±8.61 169.38±7.99 169.15±7.93 170.80±7.00 < 0.001
Weight (kg) 66.57±12.6 62.68±11.49 71.22±11.72 69.90±11.53 75.46±11.37 < 0.001
BMI (kg/m2) 23.60±3.35 22.64±3.08 24.74±3.18 24.35±3.13 25.81±3.13 < 0.001
WC (cm) 79.42±9.41 76.37±8.76 83.17±8.29 82.07±8.27 86.31±7.80 < 0.001
Fasting blood glucose (mg/dL) 93.92±18.97 91.19±14.35 96.25±21.13 95.56±19.51 101.19±27.48 < 0.001
Systolic blood pressure (mmHg) 119.64±13.48 117.02±12.96 122.95±13.11 121.82±13.05 125.56±13.22 < 0.001
Diastolic blood pressure (mmHg) 75.37±9.71 73.52±9.29 77.64±9.48 76.87±9.48 79.62±9.65 < 0.001
Total cholesterol (mg/dL) 191.74±34.29 183.99±30.95 202.64±34.77 195.30±33.84 210.15±36.17 < 0.001
Total cholesterol > 200 mg/dL 1,260,017 (37.72) 581,387 (28.31) 193,457 (50.85) 141,076 (42.54) 344,097 (59.82) < 0.001
Total cholesterol > 240 mg/dL 288,645 (8.64) 93,237 (4.54) 51,878 (13.64) 32,061 (9.67) 111,469 (19.38) < 0.001
Triglycerides (mg/dL) 129.34±88.30 83.09±29.64 207.16±67.37 108.37±27.24 255.07±104.95 < 0.001
LDL-C (mg/dL) 110.72±31.71 108.08±29.13 111.54±33.88 120.45±32.31 114.01±36.85 < 0.001
LDL-C > 130 mg/dL 844,208 (25.27) 434,012 (21.14) 105,937 (27.85) 121,430 (36.62) 182,829 (31.78) < 0.001
LDL-C > 160 mg/dL 220,348 (6.60) 96,902 (4.72) 29453(7.74) 36,888 (11.12) 57,105 (9.93) < 0.001
HDL-C, male < 40 mg/dL, female < 50 mg/dL 602,978 (18.05) 265,875 (12.95) 95,107 (25.00) 58,198 (17.55) 183,798 (31.95) < 0.001

Values are presented as number (%) or mean±SD. BMI, body mass index; HTG, hypertriglyceridemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; TG, triglyceride; WC, waist circumference. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

a) Heavy alcohol drinker was defined as consumption of alcohol more than 30 g per day,

b) Regular exercise was defined as moderate-intensity physical activity more than 5 days per week or vigorous exercise more than 3 days per week,

c) Low income was defined as the lowest quintile,

d) Obesity was defined as a BMI ≥ 25 kg/m2.

Table 2.
Incidence and risk of early-onset colorectal cancer according to TG change status among participants aged 20-49 years (National Health Insurance Service 2009-2019) by anatomic sites, if incidence age > 50 then censored
Cancer site TG change No. Cases Person-years IRa) Model 1b) Model 2c) Model 3d) Model 4e)
Colorectal Group 1 2,053,340 4,575 12,574,459 0.364 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 806 2,296,872 0.351 0.965 (0.895-1.040) 1.031 (0.955-1.113) 1.027 (0.951-1.108) 1.007 (0.932-1.088)
Group 3 331,637 731 1,955,253 0.374 1.029 (0.952-1.113) 1.036 (0.957-1.123) 1.030 (0.951-1.116) 1.013 (0.934-1.098)
Group 4 575,246 1,380 3,395,511 0.406 1.119 (1.053-1.188)f) 1.151 (1.078-1.228)f) 1.137 (1.065-1.214)f) 1.097 (1.025-1.174)f)
Colon Group 1 2,053,340 3,465 12,574,459 0.276 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 558 2,296,872 0.243 0.882 (0.807-0.964) 1.021 (0.932-1.118) 1.017 (0.928-1.115) 0.996 (0.908-1.093)
Group 3 331,637 466 1,955,253 0.238 0.866 (0.786-0.954) 0.943 (0.855-1.041) 0.938 (0.850-1.035) 0.923 (0.835-1.019)
Group 4 575,246 903 3,395,511 0.266 0.967 (0.898-1.040) 1.120 (1.034-1.212)f) 1.108 (1.023-1.199)f) 1.068 (0.983-1.160)
Rectum Group 1 2,053,340 1,110 12,574,459 0.088 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 248 2,296,872 0.108 1.224 (1.066-1.404)f) 1.063 (0.924-1.223) 1.056 (0.917-1.215) 1.040 (0.903-1.199)
Group 3 331,637 265 1,955,253 0.136 1.536 (1.344-1.757)f) 1.266 (1.104-1.452)f) 1.256 (1.095-1.441)f) 1.236 (1.076-1.419)f)
Group 4 575,246 477 3,395,511 0.140 1.593 (1.431-1.774)f) 1.232 (1.100-1.380)f) 1.214 (1.083-1.362)f) 1.175 (1.042-1.325)f)
Proximal colon Group 1 2,053,340 312 12,574,459 0.025 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 57 2,296,872 0.025 1.001 (0.755-1.327) 0.907 (0.680-1.209) 0.895 (0.671-1.193) 0.858 (0.642-1.147)
Group 3 331,637 66 1,955,253 0.034 1.363 (1.045-1.778)f) 1.147 (0.875-1.505) 1.134 (0.864-1.488) 1.100 (0.837-1.447)
Group 4 575,246 119 3,395,511 0.035 1.416 (1.146-1.749)f) 1.132 (0.905-1.417) 1.103 (0.880-1.383) 1.030 (0.814-1.305)
Distal colon Group 1 2,053,340 722 12,574,459 0.057 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 147 2,296,872 0.064 1.115 (0.934-1.332) 1.113 (0.928-1.334) 1.104 (0.920-1.323) 1.067 (0.888-1.282)
Group 3 331,637 98 1,955,253 0.050 0.874 (0.708-1.079) 0.810 (0.654-1.004) 0.804 (0.648-0.996) 0.783 (0.631-0.972)
Group 4 575,246 251 3,395,511 0.074 1.290 (1.117-1.489)f) 1.182 (1.013-1.379)f) 1.164 (0.996-1.360) 1.100 (0.935-1.294)
Unspecified Group 1 2,053,340 2,417 12,574,459 0.192 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Group 2 380,412 351 2,296,872 0.153 0.795 (0.711-0.890) 1.006 (0.897-1.127) 1.006 (0.897-1.128) 0.992 (0.883-1.113)
Group 3 331,637 299 1,955,253 0.153 0.797 (0.707-0.899) 0.953 (0.843-1.078) 0.950 (0.840-1.074) 0.938 (0.829-1.062)
Group 4 575,246 529 3,395,511 0.156 0.812 (0.739-0.892) 1.087 (0.982-1.203) 1.080 (0.975-1.197) 1.053 (0.946-1.171)

Analyses were done using the variables measured in 2011. HTG, hypertriglyceridemia; IR, incidence rate; TG, triglyceride. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

a) Per 1,000 person-years,

b) Model 1 was unadjusted,

c) Model 2 was adjusted for sex and age,

d) Model 3 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, and low-income status,

e) Model 4 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications,

f) Indicates statistical significance.

Table 3.
Incidence and risk of early-onset colorectal cancer according to the TG quartile in 2011 among participants aged 20-49 years by anatomic sites (National Health Insurance Service 2009-2019), if incidence age > 50 then censored
Cancer site TG change No. Cases Person-years IRa) Model 1b) Model 2c) Model 3d) Model 4e)
Colorectal Q1 838,610 1,788 5,252,074 0.340 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 1,885 5,046,719 0.374 1.098 (1.030-1.172)f) 1.077 (1.009-1.150)f) 1.078 (1.009-1.151)f) 1.071 (1.003-1.144)f)
Q3 831,296 1,892 4,948,210 0.382 1.125 (1.055-1.200)f) 1.135 (1.061-1.214)f) 1.134 (1.060-1.213)f) 1.116 (1.042-1.195)f)
Q4 835,114 1,927 4,975,091 0.387 1.140 (1.069-1.215)f) 1.193 (1.112-1.280)f) 1.184 (1.103-1.270)f) 1.145 (1.064-1.233)f)
p for trend < 0.001f) < 0.001f) < 0.001f) < 0.001f)
< 150 2,384,977 5,306 14,529,712 0.365 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 2,186 5,692,383 0.384 1.053 (1.002-1.107)f) 1.094 (1.038,1.154)f) 1.085 (1.029,1.145)f) 1.056 (0.999-1.116)
Colon Q1 838,610 1,376 5,252,074 0.262 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 1,408 5,046,719 0.279 1.066 (0.990-1.149) 1.090 (1.011-1.175)f) 1.091 (1.012-1.176)f) 1.084 (1.005-1.169)f)
Q3 831,296 1,325 4,948,210 0.268 1.024 (0.950-1.104) 1.131 (1.046-1.224)f) 1.131 (1.045-1.224)f) 1.113 (1.028-1.206)f)
Q4 835,114 1,283 4,975,091 0.258 0.986 (0.914-1.064) 1.188 (1.093-1.291)f) 1.181 (1.086-1.284)f) 1.144 (1.048-1.248)f)
p for trend 0.523 < 0.001f) < 0.001f) 0.002f)
< 150 2,384,977 3,931 14,529,712 0.271 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 1,461 5,692,383 0.257 0.950 (0.895-1.009) 1.088 (1.021-1.160)f) 1.081 (1.013-1.153)f) 1.053 (0.985-1.125)
Rectum Q1 838,610 412 5,252,074 0.078 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 477 5,046,719 0.095 1.205 (1.056-1.375)f) 1.035 (0.905-1.183) 1.035 (0.905-1.183) 1.029 (0.900-1.176)
Q3 831,296 567 4,948,210 0.115 1.462 (1.287-1.659)f) 1.136 (0.995-1.297) 1.133 (0.992-1.293) 1.115 (0.975-1.275)
Q4 835,114 644 4,975,091 0.129 1.651 (1.459-1.869)f) 1.198 (1.049-1.369)f) 1.183 (1.035-1.353)f) 1.143 (0.995-1.314)
p for trend < 0.001f) 0.003f) 0.006f) 0.033f)
< 150 2,384,977 1,375 14,529,712 0.095 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 725 5,692,383 0.127 1.346 (1.231-1.473)f) 1.109 (1.010-1.218)f) 1.097 (0.997-1.206) 1.066 (0.966-1.175)
Proximal colon Q1 838,610 104 5,252,074 0.020 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 139 5,046,719 0.028 1.393 (1.080-1.796)f) 1.217 (0.942-1.574) 1.210 (0.936-1.565) 1.191 (0.920-1.541)
Q3 831,296 156 4,948,210 0.032 1.595 (1.245-2.045)f) 1.296 (1.001-1.677)f) 1.279 (0.987-1.657) 1.230 (0.946-1.599)
Q4 835,114 155 4,975,091 0.031 1.577 (1.230-2.021)f) 1.222 (0.936-1.596)f) 1.190 (0.910-1.558) 1.106 (0.837-1.462)
p for trend < 0.001f) 0.161 0.236 0.552
< 150 2,384,977 378 14,529,712 0.026 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 176 5,692,383 0.031 1.190 (0.995-1.423) 1.016 (0.842-1.225) 0.996 (0.824-1.203) 0.941 (0.774-1.144)
Distal Colon Q1 838,610 263 5,252,074 0.050 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 295 5,046,719 0.058 1.169 (0.990-1.380) 1.088 (0.920-1.287) 1.086 (0.918-1.285) 1.074 (0.907-1.271)
Q3 831,296 309 4,948,210 0.062 1.249 (1.060-1.472)f) 1.150 (0.969-1.365) 1.144 (0.963-1.358) 1.113 (0.935-1.324)
Q4 835,114 351 4,975,091 0.071 1.411 (1.203-1.656)f) 1.307 (1.099-1.555)f) 1.289 (1.082-1.536)f) 1.224 (1.020-1.469)f)
p for trend < 0.001f) 0.002f) 0.004f) 0.030f)
< 150 2,384,977 820 14,529,712 0.056 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 398 5,692,383 0.070 1.240 (1.100-1.398)f) 1.197 (1.054-1.359)f) 1.184 (1.041-1.345)f) 1.139 (0.997-1.300)
Unspecified Q1 838,610 1,004 5,252,074 0.191 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Q2 835,615 965 5,046,719 0.191 1.002 (0.917-1.094) 1.075 (0.984-1.176) 1.078 (0.986-1.179) 1.074 (0.982-1.175)
Q3 831,296 857 4,948,210 0.173 0.908 (0.829-0.995) 1.112 (1.011-1.222)f) 1.115 (1.014-1.226)f) 1.105 (1.003-1.216)f)
Q4 835,114 770 4,975,091 0.155 0.811 (0.738-0.891) 1.144 (1.032-1.267)f) 1.143 (1.031-1.268)f) 1.121 (1.007-1.249)f)
p for trend < 0.001f) 0.007f) 0.008f) 0.027f)
< 150 2,384,977 2,716 14,529,712 0.187 1 (reference) 1 (reference) 1 (reference) 1 (reference)
≥ 150 955,658 880 5,692,383 0.155 0.828 (0.767-0.893) 1.059 (0.976-1.149) 1.056 (0.973-1.146) 1.037 (0.953-1.128)

Analyses were done using the variables measured in 2011. TG, triglyceride.

a) IR, incidence rate, per 1,000 person-years,

b) Model 1 was unadjusted,

c) Model 2 was adjusted for sex and age,

d) Model 3 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, and low-income status,

e) Model 4 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications. TG levels are divided into quartiles (Q1: < 71 mg/dL, Q2: 71-104 mg/dL, Q3: 105-160 mg/dL, Q4: ≥ 161 mg/dL),

f) Indicates statistical significance.

Table 4.
Hazard ratios of early onset colorectal cancer according to the change of TG status among participants aged 20-49 years (National Health Insurance Service 2009-2019) by subgroup components, if incidence age > 50 then censored
Subgroup Colorectal cancer HRs to TG change (95% CI)
Group 1 Group 2 Group 3 Group 4 p for interaction
Sex
 Male 1 (reference) 1.000 (0.910-1.099) 1.064 (0.967-1.170) 1.113 (1.032-1.200)a) 0.233
 Female 1 (reference) 1.043 (0.912-1.194) 0.897 (0.770-1.045) 1.051 (0.894-1.236)
Age (yr)
 20-29 1 (reference) 1.018 (0.721-1.437) 1.045 (0.690-1.581) 1.410 (0.993-2.001) 0.528
 30-39 1 (reference) 0.946 (0.830-1.078) 0.998 (0.870-1.144) 1.135 (1.022-1.262)a)
 40-49 1 (reference) 1.041 (0.945-1.148) 1.017 (0.920-1.125) 1.062 (0.977-1.155)
Smoking status
 Non 1 (reference) 1.029 (0.935-1.133) 1.021 (0.924-1.128) 1.148 (1.050-1.254)a) 0.438
 Current 1 (reference) 0.961 (0.845-1.092) 0.988 (0.865-1.130) 1.033 (0.935-1.142)
Alcohol consumption
 Non 1 (reference) 1.012 (0.932-1.098) 0.994 (0.913-1.083) 1.094 (1.017-1.177)a) 0.577
 Heavy drinker 1 (reference) 0.985 (0.776-1.249) 1.173 (0.924-1.489) 1.130 (0.943-1.354)
Regular exercise
 Non 1 (reference) 1.029 (0.946-1.119) 1.019 (0.931-1.115) 1.095 (1.017-1.180)a) 0.636
 Regular 1 (reference) 0.904 (0.749-1.090) 0.989 (0.835-1.171) 1.106 (0.957-1.277)
Income status
 Q2-4 1 (reference) 1.011 (0.931-1.097) 1.037 (0.952-1.128) 1.083 (1.009-1.163)a) 0.134
 Low Q1 1 (reference) 0.980 (0.788-1.220) 0.837 (0.656-1.069) 1.253 (1.040-1.510)a)
Obesity
 No 1 (reference) 1.012 (0.915-1.118) 0.983 (0.888-1.089) 1.102 (1.004-1.210)a) 0.816
 Yes 1 (reference) 1.005 (0.890-1.135) 1.060 (0.931-1.206) 1.098 (0.998-1.209)
Diabetes mellitus
 No 1 (reference) 1.015 (0.938-1.098) 1.005 (0.925-1.092) 1.078 (1.005-1.157)a) 0.152
 Yes 1 (reference) 0.927 (0.638-1.348) 1.209 (0.855-1.709) 1.374 (1.064-1.775)a)
Hypertension
 No 1 (reference) 1.012 (0.930-1.101) 1.003 (0.919-1.095) 1.073 (0.995-1.157) 0.519
 Yes 1 (reference) 1.000 (0.826-1.211) 1.075 (0.885-1.306) 1.196 (1.037-1.379)a)
Anti-dyslipidemia medications
 No 1 (reference) 1.000 (0.924-1.082) 0.993 (0.914-1.079) 1.094 (1.020-1.173)a) 0.144
 Yes 1 (reference) 1.341 (0.875-2.054) 1.527 (1.061-2.195)a) 1.316 (0.962-1.801)
Total cholesterol (mg/dL)
 < 200 1 (reference) 1.000 (0.898-1.114) 1.020 (0.919-1.132) 1.088 (0.988-1.199) 0.992
 ≥ 200 1 (reference) 1.005 (0.900-1.123) 0.998 (0.882-1.129) 1.093 (0.998-1.197)
Total cholesterol (mg/dL)
 < 240 1 (reference) 1.000 (0.920-1.086) 1.014 (0.932-1.103) 1.089 (1.012-1.172)a) 0.990
 ≥ 240 1 (reference) 1.018 (0.815-1.271) 0.980 (0.753-1.274) 1.093 (0.916-1.304)
HDL-C
 M > 40 mg/dL/F > 50 mg/dL 1 (reference) 1.034 (0.946-1.130) 1.027 (0.940-1.122) 1.112 (1.028-1.204)a) 0.551
 M ≤ 40 mg/dL/F ≤ 50 mg/dL 1 (reference) 0.922 (0.788-1.078) 0.949 (0.789-1.141) 1.047 (0.925-1.185)
LDL-C (mg/dL)
 < 130 1 (reference) 0.989 (0.903-1.083) 1.031 (0.935-1.137) 1.077 (0.994-1.166) 0.620
 ≥ 130 1 (reference) 1.054 (0.914-1.216) 0.988 (0.861-1.133) 1.145 (1.021-1.283)a)
LDL-C (mg/dL)
 < 160 1 (reference) 1.007 (0.929-1.092) 1.000 (0.919-1.089) 1.092 (1.017-1.172)a) 0.896
 ≥ 160 1 (reference) 0.998 (0.757-1.315) 1.096 (0.860-1.397) 1.139 (0.924-1.403)
Abdominal obesity
 No 1 (reference) 1.018 (0.934-1.110) 1.048 (0.960-1.144) 1.112 (1.030-1.201)a) 0.175
 Yes 1 (reference) 0.922 (0.780-1.091) 0.844 (0.697-1.023) 0.999 (0.878-1.137)

Analyses were done using the variables measured in 2011. CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; HTG, hypertriglyceridemia; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. HR was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

a) Indicates statistical significance.

  • 1. Akimoto N, Ugai T, Zhong R, Hamada T, Fujiyoshi K, Giannakis M, et al. Rising incidence of early-onset colorectal cancer: a call to action. Nat Rev Clin Oncol. 2021;18:230–43. ArticlePubMedPMCPDF
  • 2. O’Sullivan DE, Sutherland RL, Town S, Chow K, Fan J, Forbes N, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:1229–40. ArticlePubMed
  • 3. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5:1218–40. ArticlePubMedPMC
  • 4. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387:1923–34. PubMed
  • 5. Yang Z, Tang H, Lu S, Sun X, Rao B. Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis. BMJ Open. 2022;12:e052373ArticlePubMedPMC
  • 6. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjorge T, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 2011;22:291–9. ArticlePubMedPDF
  • 7. Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. Br J Cancer. 2021;124:663–70. ArticlePubMedPMCPDF
  • 8. Jin EH, Han K, Lee DH, Shin CM, Lim JH, Choi YJ, et al. Association between metabolic syndrome and the risk of colorectal cancer diagnosed before age 50 years according to tumor location. Gastroenterology. 2022;163:637–48. ArticlePubMed
  • 9. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333. ArticlePubMed
  • 10. Lee CH, Han KD, Kim DH, Kwak MS. The repeatedly elevated fatty liver index is associated with increased mortality: a population-based cohort study. Front Endocrinol (Lausanne). 2021;12:638615.ArticlePubMedPMC
  • 11. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1–203. ArticlePubMed
  • 12. Cho JH, Shin CM, Han KD, Yoon H, Park YS, Kim N, et al. Abdominal obesity increases risk for esophageal cancer: a nationwide population-based cohort study of South Korea. J Gastroenterol. 2020;55:307–16. ArticlePubMedPDF
  • 13. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997;6:863–73. PubMed
  • 14. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147–54. ArticlePubMed
  • 15. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:412–8. PubMed
  • 16. Tsushima M, Nomura AM, Lee J, Stemmermann GN. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci. 2005;50:499–505. ArticlePubMedPDF
  • 17. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36. ArticlePubMed
  • 18. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18:240–7. ArticlePubMed
  • 19. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011;60:1094–102. ArticlePubMed
  • 20. Agnoli C, Grioni S, Sieri S, Sacerdote C, Vineis P, Tumino R, et al. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. Cancer Epidemiol. 2014;38:144–51. ArticlePubMed
  • 21. Lu Y, Ness-Jensen E, Hveem K, Martling A. Metabolic predispositions and increased risk of colorectal adenocarcinoma by anatomical location: a large population-based cohort study in Norway. Am J Epidemiol. 2015;182:883–93. ArticlePubMed
  • 22. Chandler PD, Song Y, Lin J, Zhang S, Sesso HD, Mora S, et al. Lipid biomarkers and long-term risk of cancer in the Women’s Health Study. Am J Clin Nutr. 2016;103:1397–407. ArticlePubMedPMC
  • 23. Katzke VA, Sookthai D, Johnson T, Kuhn T, Kaaks R. Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. BMC Med. 2017;15:218.ArticlePubMedPMCPDF
  • 24. Li X, Chen H, Wang G, Feng X, Lyu Z, Wei L, et al. Metabolic syndrome components and the risk of colorectal cancer: a population-based prospective study in Chinese men. Front Oncol. 2019;9:1047.ArticlePubMedPMC
  • 25. Hsu SH, Syu DK, Chen YC, Liu CK, Sun CA, Chen M. The association between hypertriglyceridemia and colorectal cancer: a long-term community cohort study in Taiwan. Int J Environ Res Public Health. 2022;19:7804.ArticlePubMedPMC
  • 26. Jung YS, Ryu S, Chang Y, Yun KE, Park JH, Kim HJ, et al. Risk factors for colorectal neoplasia in persons aged 30 to 39 years and 40 to 49 years. Gastrointest Endosc. 2015;81:637–45. ArticlePubMed
  • 27. Chen J, Iverson D. Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer. Cancer Causes Control. 2012;23:1767–73. ArticlePubMedPDF
  • 28. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679–87. ArticlePubMed
  • 29. Coleman O, Ecker M, Haller D. Dysregulated lipid metabolism in colorectal cancer. Curr Opin Gastroenterol. 2022;38:162–7. ArticlePubMed
  • 30. Ecker J, Benedetti E, Kindt AS, Horing M, Perl M, Machmuller AC, et al. The colorectal cancer lipidome: identification of a robust tumor-specific lipid species signature. Gastroenterology. 2021;161:910–23. ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Obesity-Associated Colorectal Cancer
      Lucia Gonzalez-Gutierrez, Omar Motiño, Daniel Barriuso, Juan de la Puente-Aldea, Lucia Alvarez-Frutos, Guido Kroemer, Roberto Palacios-Ramirez, Laura Senovilla
      International Journal of Molecular Sciences.2024; 25(16): 8836.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study
      Cancer Res Treat. 2024;56(3):825-837.   Published online December 20, 2023
      DOI: https://doi.org/10.4143/crt.2023.753
      Close
    • XML DownloadXML Download
    • 0
    • 1
    • 2
    The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study
    Image Image Image
    Fig. 1. Flowchart showing the enrollment process for the study cohort. CRC, colorectal cancer.
    Fig. 2. Flowchart showing the follow-up process of each participant according to triglyceride (TG) status in 2009 and 2011; group 1 (serum TG < 150 mg/dL both in 2009 and 2011), group 2 (serum TG < 150 mg/dL in 2009 and TG ≥ 150 mg/dL in 2011), group 3 (serum TG ≥ 150 mg/dL in 2009 and TG < 150 mg/dL in 2011), and group 4 (serum TG ≥ 150 mg/dL both in 2009 and 2011). EoCRC, early-onset colorectal cancer.
    Fig. 3. Kaplan-Meier curves depicting the incidence probability for colorectal cancer according to change in triglyceride (TG) status; normal TG-persisted (group 1), normal to hypertriglyceridemia (HTG) (group 2), HTG to normal (group 3) and HTG-persisted (group 4) groups, if incidence age > 50 then censored (p=0.001 by log-rank test).

    Fig. 1.

    Fig. 2.

    Fig. 3.

    The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study
    Characteristic Total (n=3,340,635) TG change
    		 p-value
    Group 1 (n=2,053,340) Group 2 (n=380,412) Group 3 (n=331,637) Group 4 (n=575,246)
    Male sex 2,122,940 (63.55) 1,033,338 (50.32) 300,970 (79.12) 263,256 (79.38) 525,376 (91.33) < 0.001
    Age at recruitment (yr) 38.32±6.90 37.73±7.20 38.53±6.60 39.34±6.36 39.72±5.91 < 0.001
     20-29 433,246 (12.97) 342,650 (16.69) 38,476 (10.11) 24,975 (7.53) 27,145 (4.72) < 0.001
     30-39 1,274,575 (38.15) 750,788 (36.56) 158,592 (41.69) 129,336 (39.00) 235,859 (41.00)
     40-49 1,632,814 (48.88) 959,902 (46.75) 183,344 (48.20) 177,326 (53.47) 312,242 (54.28)
    Current smoker 1,079,951 (32.33) 489,245 (23.83) 158,728 (41.73) 132,645 (40.00) 299,333 (52.04) < 0.001
    Heavy alcohol drinkera) 289,752 (8.67) 118,700 (5.78) 45,604 (11.99) 36,063 (10.87) 89,385 (15.54) < 0.001
    Regular exerciseb) 583,556 (17.47) 361,457 (17.60) 60,225 (15.83) 68,297 (20.59) 93,577 (16.27) < 0.001
    Low incomec) 424,479 (12.71) 298,342 (14.53) 41,102 (10.80) 36,254 (10.93) 48,781 (8.48) < 0.001
    Obesityd) 1,053,807 (31.55) 420,895 (20.50) 167,891 (44.13) 129,419 (39.02) 335,602 (58.34) < 0.001
    Diabetes mellitus 130,071 (3.89) 40,703 (1.98) 18,831 (4.95) 17,979 (5.42) 52,558 (9.14) < 0.001
    Hypertension 423,587 (12.68) 172,561 (8.40) 62,449 (16.42) 54,413 (16.41) 134,164 (23.32) < 0.001
    Anti-dyslipidemia medications 102,555 (3.07) 30,863 (1.50) 12,182 (3.20) 18,348 (5.53) 41,162 (7.16) < 0.001
    Height (cm) 167.52±8.46 165.99±8.61 169.38±7.99 169.15±7.93 170.80±7.00 < 0.001
    Weight (kg) 66.57±12.6 62.68±11.49 71.22±11.72 69.90±11.53 75.46±11.37 < 0.001
    BMI (kg/m2) 23.60±3.35 22.64±3.08 24.74±3.18 24.35±3.13 25.81±3.13 < 0.001
    WC (cm) 79.42±9.41 76.37±8.76 83.17±8.29 82.07±8.27 86.31±7.80 < 0.001
    Fasting blood glucose (mg/dL) 93.92±18.97 91.19±14.35 96.25±21.13 95.56±19.51 101.19±27.48 < 0.001
    Systolic blood pressure (mmHg) 119.64±13.48 117.02±12.96 122.95±13.11 121.82±13.05 125.56±13.22 < 0.001
    Diastolic blood pressure (mmHg) 75.37±9.71 73.52±9.29 77.64±9.48 76.87±9.48 79.62±9.65 < 0.001
    Total cholesterol (mg/dL) 191.74±34.29 183.99±30.95 202.64±34.77 195.30±33.84 210.15±36.17 < 0.001
    Total cholesterol > 200 mg/dL 1,260,017 (37.72) 581,387 (28.31) 193,457 (50.85) 141,076 (42.54) 344,097 (59.82) < 0.001
    Total cholesterol > 240 mg/dL 288,645 (8.64) 93,237 (4.54) 51,878 (13.64) 32,061 (9.67) 111,469 (19.38) < 0.001
    Triglycerides (mg/dL) 129.34±88.30 83.09±29.64 207.16±67.37 108.37±27.24 255.07±104.95 < 0.001
    LDL-C (mg/dL) 110.72±31.71 108.08±29.13 111.54±33.88 120.45±32.31 114.01±36.85 < 0.001
    LDL-C > 130 mg/dL 844,208 (25.27) 434,012 (21.14) 105,937 (27.85) 121,430 (36.62) 182,829 (31.78) < 0.001
    LDL-C > 160 mg/dL 220,348 (6.60) 96,902 (4.72) 29453(7.74) 36,888 (11.12) 57,105 (9.93) < 0.001
    HDL-C, male < 40 mg/dL, female < 50 mg/dL 602,978 (18.05) 265,875 (12.95) 95,107 (25.00) 58,198 (17.55) 183,798 (31.95) < 0.001
    Cancer site TG change No. Cases Person-years IRa) Model 1b) Model 2c) Model 3d) Model 4e)
    Colorectal Group 1 2,053,340 4,575 12,574,459 0.364 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 806 2,296,872 0.351 0.965 (0.895-1.040) 1.031 (0.955-1.113) 1.027 (0.951-1.108) 1.007 (0.932-1.088)
    Group 3 331,637 731 1,955,253 0.374 1.029 (0.952-1.113) 1.036 (0.957-1.123) 1.030 (0.951-1.116) 1.013 (0.934-1.098)
    Group 4 575,246 1,380 3,395,511 0.406 1.119 (1.053-1.188)f) 1.151 (1.078-1.228)f) 1.137 (1.065-1.214)f) 1.097 (1.025-1.174)f)
    Colon Group 1 2,053,340 3,465 12,574,459 0.276 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 558 2,296,872 0.243 0.882 (0.807-0.964) 1.021 (0.932-1.118) 1.017 (0.928-1.115) 0.996 (0.908-1.093)
    Group 3 331,637 466 1,955,253 0.238 0.866 (0.786-0.954) 0.943 (0.855-1.041) 0.938 (0.850-1.035) 0.923 (0.835-1.019)
    Group 4 575,246 903 3,395,511 0.266 0.967 (0.898-1.040) 1.120 (1.034-1.212)f) 1.108 (1.023-1.199)f) 1.068 (0.983-1.160)
    Rectum Group 1 2,053,340 1,110 12,574,459 0.088 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 248 2,296,872 0.108 1.224 (1.066-1.404)f) 1.063 (0.924-1.223) 1.056 (0.917-1.215) 1.040 (0.903-1.199)
    Group 3 331,637 265 1,955,253 0.136 1.536 (1.344-1.757)f) 1.266 (1.104-1.452)f) 1.256 (1.095-1.441)f) 1.236 (1.076-1.419)f)
    Group 4 575,246 477 3,395,511 0.140 1.593 (1.431-1.774)f) 1.232 (1.100-1.380)f) 1.214 (1.083-1.362)f) 1.175 (1.042-1.325)f)
    Proximal colon Group 1 2,053,340 312 12,574,459 0.025 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 57 2,296,872 0.025 1.001 (0.755-1.327) 0.907 (0.680-1.209) 0.895 (0.671-1.193) 0.858 (0.642-1.147)
    Group 3 331,637 66 1,955,253 0.034 1.363 (1.045-1.778)f) 1.147 (0.875-1.505) 1.134 (0.864-1.488) 1.100 (0.837-1.447)
    Group 4 575,246 119 3,395,511 0.035 1.416 (1.146-1.749)f) 1.132 (0.905-1.417) 1.103 (0.880-1.383) 1.030 (0.814-1.305)
    Distal colon Group 1 2,053,340 722 12,574,459 0.057 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 147 2,296,872 0.064 1.115 (0.934-1.332) 1.113 (0.928-1.334) 1.104 (0.920-1.323) 1.067 (0.888-1.282)
    Group 3 331,637 98 1,955,253 0.050 0.874 (0.708-1.079) 0.810 (0.654-1.004) 0.804 (0.648-0.996) 0.783 (0.631-0.972)
    Group 4 575,246 251 3,395,511 0.074 1.290 (1.117-1.489)f) 1.182 (1.013-1.379)f) 1.164 (0.996-1.360) 1.100 (0.935-1.294)
    Unspecified Group 1 2,053,340 2,417 12,574,459 0.192 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Group 2 380,412 351 2,296,872 0.153 0.795 (0.711-0.890) 1.006 (0.897-1.127) 1.006 (0.897-1.128) 0.992 (0.883-1.113)
    Group 3 331,637 299 1,955,253 0.153 0.797 (0.707-0.899) 0.953 (0.843-1.078) 0.950 (0.840-1.074) 0.938 (0.829-1.062)
    Group 4 575,246 529 3,395,511 0.156 0.812 (0.739-0.892) 1.087 (0.982-1.203) 1.080 (0.975-1.197) 1.053 (0.946-1.171)
    Cancer site TG change No. Cases Person-years IRa) Model 1b) Model 2c) Model 3d) Model 4e)
    Colorectal Q1 838,610 1,788 5,252,074 0.340 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 1,885 5,046,719 0.374 1.098 (1.030-1.172)f) 1.077 (1.009-1.150)f) 1.078 (1.009-1.151)f) 1.071 (1.003-1.144)f)
    Q3 831,296 1,892 4,948,210 0.382 1.125 (1.055-1.200)f) 1.135 (1.061-1.214)f) 1.134 (1.060-1.213)f) 1.116 (1.042-1.195)f)
    Q4 835,114 1,927 4,975,091 0.387 1.140 (1.069-1.215)f) 1.193 (1.112-1.280)f) 1.184 (1.103-1.270)f) 1.145 (1.064-1.233)f)
    p for trend < 0.001f) < 0.001f) < 0.001f) < 0.001f)
    < 150 2,384,977 5,306 14,529,712 0.365 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 2,186 5,692,383 0.384 1.053 (1.002-1.107)f) 1.094 (1.038,1.154)f) 1.085 (1.029,1.145)f) 1.056 (0.999-1.116)
    Colon Q1 838,610 1,376 5,252,074 0.262 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 1,408 5,046,719 0.279 1.066 (0.990-1.149) 1.090 (1.011-1.175)f) 1.091 (1.012-1.176)f) 1.084 (1.005-1.169)f)
    Q3 831,296 1,325 4,948,210 0.268 1.024 (0.950-1.104) 1.131 (1.046-1.224)f) 1.131 (1.045-1.224)f) 1.113 (1.028-1.206)f)
    Q4 835,114 1,283 4,975,091 0.258 0.986 (0.914-1.064) 1.188 (1.093-1.291)f) 1.181 (1.086-1.284)f) 1.144 (1.048-1.248)f)
    p for trend 0.523 < 0.001f) < 0.001f) 0.002f)
    < 150 2,384,977 3,931 14,529,712 0.271 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 1,461 5,692,383 0.257 0.950 (0.895-1.009) 1.088 (1.021-1.160)f) 1.081 (1.013-1.153)f) 1.053 (0.985-1.125)
    Rectum Q1 838,610 412 5,252,074 0.078 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 477 5,046,719 0.095 1.205 (1.056-1.375)f) 1.035 (0.905-1.183) 1.035 (0.905-1.183) 1.029 (0.900-1.176)
    Q3 831,296 567 4,948,210 0.115 1.462 (1.287-1.659)f) 1.136 (0.995-1.297) 1.133 (0.992-1.293) 1.115 (0.975-1.275)
    Q4 835,114 644 4,975,091 0.129 1.651 (1.459-1.869)f) 1.198 (1.049-1.369)f) 1.183 (1.035-1.353)f) 1.143 (0.995-1.314)
    p for trend < 0.001f) 0.003f) 0.006f) 0.033f)
    < 150 2,384,977 1,375 14,529,712 0.095 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 725 5,692,383 0.127 1.346 (1.231-1.473)f) 1.109 (1.010-1.218)f) 1.097 (0.997-1.206) 1.066 (0.966-1.175)
    Proximal colon Q1 838,610 104 5,252,074 0.020 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 139 5,046,719 0.028 1.393 (1.080-1.796)f) 1.217 (0.942-1.574) 1.210 (0.936-1.565) 1.191 (0.920-1.541)
    Q3 831,296 156 4,948,210 0.032 1.595 (1.245-2.045)f) 1.296 (1.001-1.677)f) 1.279 (0.987-1.657) 1.230 (0.946-1.599)
    Q4 835,114 155 4,975,091 0.031 1.577 (1.230-2.021)f) 1.222 (0.936-1.596)f) 1.190 (0.910-1.558) 1.106 (0.837-1.462)
    p for trend < 0.001f) 0.161 0.236 0.552
    < 150 2,384,977 378 14,529,712 0.026 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 176 5,692,383 0.031 1.190 (0.995-1.423) 1.016 (0.842-1.225) 0.996 (0.824-1.203) 0.941 (0.774-1.144)
    Distal Colon Q1 838,610 263 5,252,074 0.050 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 295 5,046,719 0.058 1.169 (0.990-1.380) 1.088 (0.920-1.287) 1.086 (0.918-1.285) 1.074 (0.907-1.271)
    Q3 831,296 309 4,948,210 0.062 1.249 (1.060-1.472)f) 1.150 (0.969-1.365) 1.144 (0.963-1.358) 1.113 (0.935-1.324)
    Q4 835,114 351 4,975,091 0.071 1.411 (1.203-1.656)f) 1.307 (1.099-1.555)f) 1.289 (1.082-1.536)f) 1.224 (1.020-1.469)f)
    p for trend < 0.001f) 0.002f) 0.004f) 0.030f)
    < 150 2,384,977 820 14,529,712 0.056 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 398 5,692,383 0.070 1.240 (1.100-1.398)f) 1.197 (1.054-1.359)f) 1.184 (1.041-1.345)f) 1.139 (0.997-1.300)
    Unspecified Q1 838,610 1,004 5,252,074 0.191 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    Q2 835,615 965 5,046,719 0.191 1.002 (0.917-1.094) 1.075 (0.984-1.176) 1.078 (0.986-1.179) 1.074 (0.982-1.175)
    Q3 831,296 857 4,948,210 0.173 0.908 (0.829-0.995) 1.112 (1.011-1.222)f) 1.115 (1.014-1.226)f) 1.105 (1.003-1.216)f)
    Q4 835,114 770 4,975,091 0.155 0.811 (0.738-0.891) 1.144 (1.032-1.267)f) 1.143 (1.031-1.268)f) 1.121 (1.007-1.249)f)
    p for trend < 0.001f) 0.007f) 0.008f) 0.027f)
    < 150 2,384,977 2,716 14,529,712 0.187 1 (reference) 1 (reference) 1 (reference) 1 (reference)
    ≥ 150 955,658 880 5,692,383 0.155 0.828 (0.767-0.893) 1.059 (0.976-1.149) 1.056 (0.973-1.146) 1.037 (0.953-1.128)
    Subgroup Colorectal cancer HRs to TG change (95% CI)
    Group 1 Group 2 Group 3 Group 4 p for interaction
    Sex
     Male 1 (reference) 1.000 (0.910-1.099) 1.064 (0.967-1.170) 1.113 (1.032-1.200)a) 0.233
     Female 1 (reference) 1.043 (0.912-1.194) 0.897 (0.770-1.045) 1.051 (0.894-1.236)
    Age (yr)
     20-29 1 (reference) 1.018 (0.721-1.437) 1.045 (0.690-1.581) 1.410 (0.993-2.001) 0.528
     30-39 1 (reference) 0.946 (0.830-1.078) 0.998 (0.870-1.144) 1.135 (1.022-1.262)a)
     40-49 1 (reference) 1.041 (0.945-1.148) 1.017 (0.920-1.125) 1.062 (0.977-1.155)
    Smoking status
     Non 1 (reference) 1.029 (0.935-1.133) 1.021 (0.924-1.128) 1.148 (1.050-1.254)a) 0.438
     Current 1 (reference) 0.961 (0.845-1.092) 0.988 (0.865-1.130) 1.033 (0.935-1.142)
    Alcohol consumption
     Non 1 (reference) 1.012 (0.932-1.098) 0.994 (0.913-1.083) 1.094 (1.017-1.177)a) 0.577
     Heavy drinker 1 (reference) 0.985 (0.776-1.249) 1.173 (0.924-1.489) 1.130 (0.943-1.354)
    Regular exercise
     Non 1 (reference) 1.029 (0.946-1.119) 1.019 (0.931-1.115) 1.095 (1.017-1.180)a) 0.636
     Regular 1 (reference) 0.904 (0.749-1.090) 0.989 (0.835-1.171) 1.106 (0.957-1.277)
    Income status
     Q2-4 1 (reference) 1.011 (0.931-1.097) 1.037 (0.952-1.128) 1.083 (1.009-1.163)a) 0.134
     Low Q1 1 (reference) 0.980 (0.788-1.220) 0.837 (0.656-1.069) 1.253 (1.040-1.510)a)
    Obesity
     No 1 (reference) 1.012 (0.915-1.118) 0.983 (0.888-1.089) 1.102 (1.004-1.210)a) 0.816
     Yes 1 (reference) 1.005 (0.890-1.135) 1.060 (0.931-1.206) 1.098 (0.998-1.209)
    Diabetes mellitus
     No 1 (reference) 1.015 (0.938-1.098) 1.005 (0.925-1.092) 1.078 (1.005-1.157)a) 0.152
     Yes 1 (reference) 0.927 (0.638-1.348) 1.209 (0.855-1.709) 1.374 (1.064-1.775)a)
    Hypertension
     No 1 (reference) 1.012 (0.930-1.101) 1.003 (0.919-1.095) 1.073 (0.995-1.157) 0.519
     Yes 1 (reference) 1.000 (0.826-1.211) 1.075 (0.885-1.306) 1.196 (1.037-1.379)a)
    Anti-dyslipidemia medications
     No 1 (reference) 1.000 (0.924-1.082) 0.993 (0.914-1.079) 1.094 (1.020-1.173)a) 0.144
     Yes 1 (reference) 1.341 (0.875-2.054) 1.527 (1.061-2.195)a) 1.316 (0.962-1.801)
    Total cholesterol (mg/dL)
     < 200 1 (reference) 1.000 (0.898-1.114) 1.020 (0.919-1.132) 1.088 (0.988-1.199) 0.992
     ≥ 200 1 (reference) 1.005 (0.900-1.123) 0.998 (0.882-1.129) 1.093 (0.998-1.197)
    Total cholesterol (mg/dL)
     < 240 1 (reference) 1.000 (0.920-1.086) 1.014 (0.932-1.103) 1.089 (1.012-1.172)a) 0.990
     ≥ 240 1 (reference) 1.018 (0.815-1.271) 0.980 (0.753-1.274) 1.093 (0.916-1.304)
    HDL-C
     M > 40 mg/dL/F > 50 mg/dL 1 (reference) 1.034 (0.946-1.130) 1.027 (0.940-1.122) 1.112 (1.028-1.204)a) 0.551
     M ≤ 40 mg/dL/F ≤ 50 mg/dL 1 (reference) 0.922 (0.788-1.078) 0.949 (0.789-1.141) 1.047 (0.925-1.185)
    LDL-C (mg/dL)
     < 130 1 (reference) 0.989 (0.903-1.083) 1.031 (0.935-1.137) 1.077 (0.994-1.166) 0.620
     ≥ 130 1 (reference) 1.054 (0.914-1.216) 0.988 (0.861-1.133) 1.145 (1.021-1.283)a)
    LDL-C (mg/dL)
     < 160 1 (reference) 1.007 (0.929-1.092) 1.000 (0.919-1.089) 1.092 (1.017-1.172)a) 0.896
     ≥ 160 1 (reference) 0.998 (0.757-1.315) 1.096 (0.860-1.397) 1.139 (0.924-1.403)
    Abdominal obesity
     No 1 (reference) 1.018 (0.934-1.110) 1.048 (0.960-1.144) 1.112 (1.030-1.201)a) 0.175
     Yes 1 (reference) 0.922 (0.780-1.091) 0.844 (0.697-1.023) 0.999 (0.878-1.137)
    Table 1. Baseline characteristics of enrolled National Health Insurance Service cohort in 2011 according to TG change status from 2009-2011

    Values are presented as number (%) or mean±SD. BMI, body mass index; HTG, hypertriglyceridemia; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; TG, triglyceride; WC, waist circumference. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

    Heavy alcohol drinker was defined as consumption of alcohol more than 30 g per day,

    Regular exercise was defined as moderate-intensity physical activity more than 5 days per week or vigorous exercise more than 3 days per week,

    Low income was defined as the lowest quintile,

    Obesity was defined as a BMI ≥ 25 kg/m2.

    Table 2. Incidence and risk of early-onset colorectal cancer according to TG change status among participants aged 20-49 years (National Health Insurance Service 2009-2019) by anatomic sites, if incidence age > 50 then censored

    Analyses were done using the variables measured in 2011. HTG, hypertriglyceridemia; IR, incidence rate; TG, triglyceride. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

    Per 1,000 person-years,

    Model 1 was unadjusted,

    Model 2 was adjusted for sex and age,

    Model 3 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, and low-income status,

    Model 4 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications,

    Indicates statistical significance.

    Table 3. Incidence and risk of early-onset colorectal cancer according to the TG quartile in 2011 among participants aged 20-49 years by anatomic sites (National Health Insurance Service 2009-2019), if incidence age > 50 then censored

    Analyses were done using the variables measured in 2011. TG, triglyceride.

    IR, incidence rate, per 1,000 person-years,

    Model 1 was unadjusted,

    Model 2 was adjusted for sex and age,

    Model 3 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, and low-income status,

    Model 4 was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications. TG levels are divided into quartiles (Q1: < 71 mg/dL, Q2: 71-104 mg/dL, Q3: 105-160 mg/dL, Q4: ≥ 161 mg/dL),

    Indicates statistical significance.

    Table 4. Hazard ratios of early onset colorectal cancer according to the change of TG status among participants aged 20-49 years (National Health Insurance Service 2009-2019) by subgroup components, if incidence age > 50 then censored

    Analyses were done using the variables measured in 2011. CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; HTG, hypertriglyceridemia; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride. HR was adjusted for sex, age, smoking status, alcohol consumption, regular exercise, low-income status, obesity, diabetes mellitus, hypertension, and anti-dyslipidemia medications. Group 1 (normal TG-persisted), Group 2 (normal to HTG), Group 3 (HTG to normal), Group 4 (HTG-persisted).

    Indicates statistical significance.

    Table 1.

    Table 2.

    Table 3.

    Table 4.

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP